Human tryptophan hydroxyise has been expressed as a soluble and active form in Escherichia coli by fusion with an affinity tag, maltose-binding protein. The iron, catalyzes the pterin-dependent hydroxylation ofL-tryptophan to form 5-hydroxytryptophan (5-HTP) (1). Within the central nervous system, this reaction is the first and ratelimiting step in biosynthesis of the neurotransmitter 5-hydroxytryptamine (gerotonin) (2). Serotonin in the central nervous system has possible roles in regulation of body temperature and control of different behaviors as well as in the etiology of affective disorders (3). In the endocrine pineal gland, the hydroxylation oftryptophan by TPH is the first but not rate-limiting step in the biosynthesis of melatonin (4), which is a physiologically important bioregulatory molecule (5).
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TPH is one member of a family of pterin-dependent aromatic amino acid hydroxylases, which also includes phenylalanine hydroxylase [PAH; phenylalanine 4-monooxygenase; L-phenylalanine, tetrahydrobiopterin:oxygen oxidoreductase (4-hydroxylating), EC 1.14. 16 .1] and tyrosine hydroxylase [TH; tyrosine 3-monooxygenase; L-tyrosine, tetrahydrobiopterin:oxygen oxidoreductase (3-hydroxylating), EC 1.14.16.2] (1, 6-8). Due to its limited availability and extreme instability, biochemical characterization of TPH has been hampered (9, 10) . In contrast, the other two enzymes, PAH and TH, have been relatively well studied (11, 12) . Successful expression of PAH and TH in heterologous systems, such as Escherichia coli and insect cells, has been helpful in biochemical studies of both enzymes (13) (14) (15) (16) .
TPHs from brain, pineal gland, and mast cells exhibit distinct biochemical characteristics (17, 18) . Biochemical differences between TPHs from rat brain and pineal gland are due to posttranslational modification (17) . cDNA clones encoding TPH have been isolated from rabbit and rat pineal gland (19, 20) , rat brain (17) , and mouse mastocytoma and human carcinoid cell lines (21, 22) . TPH cDNA, recently isolated from human brain in this laboratory, has been expressed in E. coli, but the expressed protein is largely insoluble (J. Tipper, B. A. Citron, P. Ribeiro, and S.K., unpublished data). Efforts attempting to denature and renature insoluble TPH Oligonucleotide-Directed Mutagenesis. A phagemid in vitro mutagenesis kit (Bio-Rad) was used. Single-stranded uracilrich DNA templates of phTPH1 or phTPH2 were prepared as described (23) . Mutagenic primers used were as follows: o227, 5'-GAG GGA AGG AATG ATT GAA G-3'; o302, 5'-GGC GCT GGC IAA CTT TCT TCT ATC-3'; o304,  5'-GTT CTT TCT GTG L AC CCA GAT AAT TTT-3';  o306, 5'-ATG AGA GAA TTC I  AAA ACA ATT AAG  C-3'; o307, 5'-ACA CGA AGC ATT TAA EGA TCC TGA  AAG-3'; o338, 5'-TG AAC GAG CTG CAG IAA TGA TCT   TGA CGT- Construction of TPH Expression Plsnids. phTPH1 was constructed by insertion of the 1.4-kb Nde I/BamHI fragment of H1A between the Xmn I and BamHI sites of pMAL-c2 (New England Biolabs). phTPH2 was derived from phTPH1 by deletion of an extra nucleotide with mutagenic primer o227. A 0.85-kb fragment of phTPH2 was cloned into pMAL-c2 to yield phTPH7. Site-directed mutagenesis with o304, o304/o307, and o304/o338 was used to convert ph-TPH2 to plasmids phTPH4, phTPH9, and phTPH16, respectively; 1.0-kb EcoRI/BamHI fragments from phTPH4, ph-TPH9, and phTPH16 were then ligated to EcoRI/BamHIdigested pMAL-c2 to obtain phTPH10, phTPH11, and phTPH17, respectively. Primers o302, o306, o307, and o338 were used to introduce termination codons into the TPH coding sequence in phTPH2, which yielded phTPH3, ph-TPH5, phTPH6, and phTPH15, respectively.
Expression and Purification of Human TPH. Cultures of E. coli strain DH5 (GIBCO/BRL), transformed by phTPH2 or its derivatives, were grown and induced for expression as described (13, 24 Solutions of BH4 and 6MPH4 were prepared in 5 mM HCO as described (26) . Protein concentrations were determined with the BCA reagent (Pierce) using bovine serum albumin as the standard. To minimize the interference by tryptophan in the BCA method, protein samples containing tryptophan were pretreated by acetone precipitation. The precipitates were washed with 75% ethanol and redissolved in 0.9%6 SDS/36 mM NaOH.
Other Method. Western immunoanalyses were performed as described (27) . To obtain kinetic parameters, experimental data were fitted to the Michaelis-Menten equation with a Macintosh program, Enzyme Kinetics 1.0c, developed by D. G. Gilbert (Indiana University). In the case of inhibition by high concentrations of substrate or cofactor, data obtained at low concentrations were used to calculate apparent Km values.
RESULTS
Expressin and Purification of Human TPH. To achieve high-level expression and permit affinity purification of active TPH, a fusion protein expression and purification system was used (28) . Plasmid phTPH2 was constructed to express a fusion protein consisting of MBP, affinity tag at the N terminus, followed by a linker peptide, and human TPH at the C terminus (Fig. 1) . The single-stranded form of phTPH2 could be rescued for site-directed mutagenesis. Plasmid phTPH2, therefore, provided a convenient vector for expression, mutagenesis, and purification of human TPH.
Because of the well-documented instability of TPH (9, 10, 29), buffer A was introduced to stabilize the enzyme. Iron(II) was included in buffer A to prevent iron loss from TPH. Due to the presence of Fe2+, fresh buffer A had a greenish color. Total and soluble bacterial protein extracts from phTPH2-containing DH5 were analyzed by SDS/PAGE and revealed an induced band of 91 kDa, which remained in the soluble protein extract (Fig. 2A) (30) , the available anti-rat PAH antibodies were used. The antibodies reacted with the induced 91-kDa band as well as with several smaller bands (Fig. 2B) .
Soluble protein extracts from E. coli cells, grown under different conditions, were assayed for TPH activity. The specific activity of the soluble extract from DH5 harboring phTPH2 was estimated to be >1.7 units per mg, whereas no activity was detected from protein extracts made from the same host transformed with vector pMAL-c2. Human TPH, therefore, was expressed from phTPH2 as a soluble and active fusion protein.
TPH fusion protein was expressed in 2-to 4-liter cultures of E. coli DH5, transformed with plasmid phTPH2, and purified by affinity chromatography on amylose resin. TPH precipitated when the enzyme purified in buffer A was dialyzed against the same buffer with a lower concentration of Tween 20 (0.01%), indicating that Tween 20 is important for TPH solubility. When buffer A was used, the purified enzyme retained --60%o activity after 3 months at -80TC. As judged by SDS/PAGE (Fig. 2C) , the fusion protein was close to homogeneity, with a major band of 91 kDa (=80%6) and some minor smaller bands. The 91-kDa band as well as some minor bands crossreacted with anti-rat PAH polyclonal antibodies.
Attempts were made to cleave intact TPH from the purified fusion protein by digestion with factor Xa protease (Fig. 1B) . Probably because of nonspecific digestion by the protease at sites partially homologous to its recognition sequence, only partial digestion of the fusion protein gave intact TPH. Cleaved MBP was removed by ammonium sulfate fractionation, which yielded a mixture of cleaved and fused forms of TPH. Efforts aimed at separating these two forms were unsuccessful (data not shown). Since TPH was reported to be a tetramer (10) , the cleaved and fused forms of TPH might exist as tight heterocomplexes, which made it very difficult to separate the two forms. We were also unsuccessful in attempting to cleave the fusion protein while bound to amylose resin. Furthermore, digestion of fused TPH by factor Xa protease promoted formation of precipitates consisting of the cleaved and fused forms ofTPH. Because of the difficulties we experienced in obtaining cleaved TPH, the fused form was used for the experiments described below.
Kineic Properties of Fused TPH. Different from the results for rabbit and mouse brain TPHs (18, 25) , human TPH is more active with BH4 than with 6MPH4. In the presence of the natural cofactor, BH4, the purified fusion protein has a specific activity of 86 units per mg of fusion protein, which is equal to a calculated value of 160 units per mg of TPH. When the synthetic analog, 6MPH4, was used as the cofactor, the specific activity was found to be 62 units per mg of TPH, which is close to the reported value of82 units/mg for the less active form of the rat brain enzyme but lower than the value of 374 units/mg for the more active one (10) .
As reported for the rabbit brain enzyme (25, 31) , fused TPH exhibits typical substrate inhibition by L-tryptophan (>0.13 mM) in the presence of BH4 (Fig. 3A) . Inhibition by excess L-tryptophan is much less evident when 6MPH4 is substituted for BH4 (Fig. 3A) . Slight inhibition is evident at high concentrations of BH4 or 6MPH4 (Fig. 3B) (10, 18, 29, 31, 32) . This wide range of values may be partially explained by the fact that different buffer systems were used for the determinations. To test this possibility, the Km for L-tryptophan was determined in different buffers. In the presence of BH4, the Km of fused TPH for L-tryptophan was found to be 26 pM in 50 mM Tris HCl (pH 7.5) and 80 pM in 50 mM NaHepes (pH 6.8). This is also consistent with the report that the Km value of TH for 6MPH4 is 24 AM in Tris HCl and 86 ,uM in another buffer (33) .
Effects of Truncations on TPH Activity. Proteolysis and deletion mutagenesis have well documented the conclusion that only the C-terminal two-thirds of PAH or TH is essential for catalytic activity, with the N-terminal one-third being the regulatory domain (34) (35) (36) (37) . TPH shares highly homologous regions with PAH and TH in the C-terminal two-thirds (19, 20) (Fig. 4) . It has been demonstrated that the C-terminal 380 residues of mouse TPH are sufficient for catalytic activity (21) . To further analyze the domain organization of TPH, a series of plasmids (Fig. 4) were constructed from phTPH2 to express mutants lacking peptides from one or both termini of human TPH.
Like full-length TPH, deletion mutants were expressed as MBP fusion proteins and purified by affinity chromatography tWhile L-tryptophan concentration was fixed at 125 ,uM, the concentration of 6MPH4 was increased from 5 to 90 ,uM for 1-444 and 92-444 and from 5 to 40 pM for 1-425. on amylose resin. As judged by SDS/PAGE (data not shown), the mutants were almost as pure as full-length TPH, with major bands of the expected sizes. The purified mutants crossreacted with polyclonal antibodies to rat PAH (data not shown). The relative activities of the mutants are included in Fig. 4 .
To analyze the regulatory function ofthe N-terminal region of human TPH, deletion mutants lacking the first 91 and 164 residues were constructed. While deletion of the N-terminal 91 residues (mutant 92-444) retains -14% of the specific activity of full-length TPH (1-444), further deletion of 73 residues (mutant 165-444) abolishes the activity, which indicates that residues between 92 and 164 are essential for catalysis. Similarly, it was shown for mouse TPH that the C-terminal 380 but not 279 amino acids are sufficient for catalytic activity (20) .
To study a possible regulatory role of the TPH C terminus, truncation mutants 1-425, 1-408, 1-389, and 1-333 were made (Fig. 4) . Whereas mutants 1-389 and 1-333 display no detectable activity, 1-425 and 1-408 have 9% and 1.3% of the specific activity of 1-444, respectively. Therefore, the C-terminal region of TPH is important for maximal activity.
It was shown that removal ofthe C-terminal 43 amino acids inactivated rat TH and that further deletion of 157 residues from the N terminus restored about one-half of the activity (37) . To extend this study to TPH, deletions were made from both termini of TPH to create mutants 92-408 and 92-425 Plasmid Enzyme phTPH2 wt (1-444) - (Fig. 4) . Both mutants have very low or no detectable activity, demonstrating that the N-and C-terminal regions of TPH are functionally different from those of rat TH.
Kinetic Parameters of Mutants 90-444 and 1-426. Among all the mutants constructed, only 92-444 and 1-425 were shown to be relatively active. To analyze effects of the deletions on other kinetic properties, these two mutants were characterized further (Fig. 3 C-F) . Similar to the wild-type enzyme, both mutants display the following properties: more active with BH4 than with 6MPH4; typical substrate inhibition by L-tryptophan in the presence of BH4; no evident substrate inhibition by L-tryptophan in the presence of 6MPH4; and slight cofactor inhibition by high concentrations of BH4. Unlike and 92-444, however, the C-terminal deletion mutant 1-425 shows a very strong inhibition by 6MPH4 (>40 ,uM) at a constant concentration of L-tryptophan.
Kinetic data similar to those shown in Fig. 3 (38) .
Just like the native rabbit brain enzyme (31) , fused TPH, in the presence of BH4, exhibits biphasic kinetics with strong inhibition by L-tryptophan at concentrations >130 ,uM. By contrast, with 6MPH4 as the cofactor, there is only slight substrate inhibition even at L-tryptophan concentrations as high as 0.5 mM. It has been observed that, in the presence of BH4, PAH (39) and TH (13, 40) also show inhibition by high concentrations of the substrates phenylalanine and tyrosine, respectively. Unlike PAH (11) and TH (37) , however, human TPH may have a higher rate of hydroxylation when BH4 rather than 6MPH4 is used as the cofactor. Among the mutants constructed to define the TPH domain organization, only the N-terminal deletion mutant 92-444 and the C-terminal deletion mutant 1-425 are relatively active, which suggests that the catalytic domain of TPH may be located between residues 92 and 425. In this respect, human TPH is analogous to PAH (34) and TH (37) . However, since 92-444 is less active than 1-444, the N-terminal region, residues 1-91, may be necessary to keep the catalytic core (residues 92-425) in the most active conformation. This is different from regulation mechanisms of PAH and TH, where the N-terminal peptides are believed to serve as inhibitory domains (34) (35) (36) (37) 41) .
Unlike 1-444 and 92-444, 1-425 shows strong inhibition by 6MPH4 (>40 pM; see Fig. 4 ). It is unclear why deletion ofthe C-terminal 19 amino acids makes TPH behave so differently, but this result may suggest that the C-terminal region is involved in functional regulation of the central catalytic domain. Since 1-425 is less active than 1-444, the N-terminal 2-kDa region may also help the catalytic core, residues 92-425, maintain the most active conformation. This is consistent with the reports that deletions of the C-terminal 43 and 20 amino acids of rat TH decrease V. by 3-and 4-fold, respectively (37, 42) . Based on these results and amino acid sequence homologies among the three hydroxylases (19, 20) , we propose that these enzymes are constituted with three functional domains: an N-terminal regulatory domain, a catalytic core, and a small C-terminal region of uncertain but important function. An "inhibitor peptide" model was previously proposed to explain the inhibitory function of the N-terminal peptide of rat liver PAH (34, 43) . It was also suggested that rat TH consists of two functional domains: the N-terminal regulatory region and the catalytic center (36) . Partial proteolysis indicated that a 5-kDa C-terminal fragment of rat liver PAH is important for the tetramerization (34) . It was also reported that the C terminus of rat TH is responsible for tetramer formation (42) . Studies on the multimerization of human TPH remain to be done.
Further investigation is needed to understand how the Nand C-terminal regions of human TPH functionally affect the central catalytic domain. It is possible that the three domains may interact with each other, which is consistent with the deletion analysis of rat TH (37) . Based on amino acid sequences of mammalian aromatic amino acid hydroxylases, Liu and Vrana (44) have predicted that these enzymes have potential leucine zippers in the catalytic domains and coiledcoil motifs in the C-terminal regions (45) . In addition, we believe that there are putative coiled-coil motifs in the N-terminal regulatory domain of human TPH. It is not yet known whether these putative motifs in different domains mediate the domain interaction.
It is obvious that conclusions drawn from fused TPH may not reflect the real nature of the native enzyme, but this system should be useful for certain purposes before the native hydroxylase becomes easily accessible.
In summary, human TPH has been expressed and purified as an active fusion protein. It has also been demonstrated that the structural determinants of catalytic activity of TPH are somewhat different from those of PAH and TH. In particular, there is no indication that the N-terminal region of TPH exerts negative control over its catalytic activity in the same way that the corresponding regions in the other two hydroxylases do over their catalytic activities.
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